Mark Granada, MD
Internal Medicine · Annandale, VANPI 1467642504
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,014 and has fallen 64.8% since, to $708 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$732
- GSK$724
- Inari Medical, Inc.$556
- Amgen$537
- Boehringer Ingelheim$501
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,73099%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $1,287 |
| Sanofi | 31 | $732 |
| GSK | 47 | $724 |
| Inari Medical, Inc. | 3 | $556 |
| Amgen | 25 | $537 |
| Boehringer Ingelheim | 25 | $501 |
| Insmed, Inc. | 12 | $242 |
| Genentech USA, Inc. | 9 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $212 |
| Baxter Healthcare | 8 | $192 |
| Pulmonx Corporation | 2 | $187 |
| Johnson & Johnson(2 entities) | 9 | $170 |
| United Therapeutics Corporation | 6 | $169 |
| Mylan Specialty L.p. | 9 | $166 |
| Grifols USA, LLC | 7 | $147 |
| Actelion Pharmaceuticals US, Inc. | 6 | $139 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Novartis | 4 | $76 |
| Verona Pharma, Inc. | 3 | $66 |
| Mallinckrodt Hospital Products Inc. | 2 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Circassia Inc. | 3 | $49 |
| Philips North America LLC | 2 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $43 |
| Electromed, Inc. | 2 | $32 |
| Vapotherm Inc | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,794 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $287,476 |
| Dupixent PenDupilumab | 53 | $209,734 |
| Fasenra PenBenralizumab | 29 | $159,913 |
| OfevNintedanib Esylate | 24 | $157,358 |
| TezspireTezepelumab-Ekko | 23 | $100,213 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $93,061 |
| XolairOmalizumab | 23 | $90,022 |
| Spiriva RespimatTiotropium Bromide | 76 | $88,359 |
| Dupixent SyringeDupilumab | 15 | $68,910 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 78 | $53,720 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $48,089 |
| NucalaMepolizumab | 13 | $46,990 |
| EliquisApixaban | 54 | $42,304 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $38,927 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $22,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta | $724 | $499,287573 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $501 | $305,400189 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,287 | $162,075149 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $60 | $12,13932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Annandale
- Connie leAnnandale$18K
- Martha MaturiAnnandale$14K
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.